Advancis looks to cut costs following trial failure

Days after its lead product failed a second Phase III trial, the CEO of Advancis told analysts that he was looking at cutting costs, including possible layoffs. Advancis had been developing a new form of the antibiotic amoxicillin, but it has now failed pivotal trials for adults and children. The biotech has about $40 million in cash on hand.

- read this report from Washington Business Journal for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.